Difference between revisions of "Androgen receptor"
Jump to navigation
Jump to search
| (4 intermediate revisions by the same user not shown) | |||
| Line 15: | Line 15: | ||
| Other = | | Other = | ||
}} | }} | ||
'''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens (testosterone, dihydrotestosterone). | '''Androgen receptor''', abbreviated '''AR''', is receptor activated by androgens ([[testosterone]], dihydrotestosterone). | ||
==Tumours with AR== | ==Tumours with AR== | ||
| Line 21: | Line 21: | ||
*Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref> | *Ovarian [[Brenner tumour]].<ref name=pmid24012099>{{Cite journal | last1 = Kuhn | first1 = E. | last2 = Ayhan | first2 = A. | last3 = Shih | first3 = IeM. | last4 = Seidman | first4 = JD. | last5 = Kurman | first5 = RJ. | title = Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. | journal = Eur J Cancer | volume = 49 | issue = 18 | pages = 3839-49 | month = Dec | year = 2013 | doi = 10.1016/j.ejca.2013.08.011 | PMID = 24012099 }}</ref> | ||
*[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref> | *[[Apocrine carcinoma of the breast]] - usu. smaller tumours.<ref name=pmid16045781>{{Cite journal | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref> | ||
*[[Prostate carcinoma with amphicrine features]].<ref name=pmid28756619>{{Cite journal | last1 = Prendeville | first1 = S. | last2 = Al-Bozom | first2 = I. | last3 = Compérat | first3 = E. | last4 = Sweet | first4 = J. | last5 = Evans | first5 = AJ. | last6 = Ben-Gashir | first6 = M. | last7 = Mete | first7 = O. | last8 = van der Kwast | first8 = TH. | last9 = Downes | first9 = MR. | title = Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin? | journal = Histopathology | volume = 71 | issue = 6 | pages = 926-933 | month = Dec | year = 2017 | doi = 10.1111/his.13330 | PMID = 28756619 }}</ref> | |||
==Antibodies== | |||
Various clone exist and they target different regions/variants; an incomplete list includes: | |||
*AR N-terminus. | |||
*AR C-terminus. | |||
*AR v7. | |||
==See also== | ==See also== | ||
*[[Immunohistochemistry]]. | *[[Immunohistochemistry]]. | ||
*[[Enzalutamide]]. | |||
*[[Abiraterone]]. | |||
==References== | ==References== | ||
Latest revision as of 13:09, 18 March 2019
| Androgen receptor | |
|---|---|
| Immunostain in short | |
| Normal staining pattern | nuclear |
| Positive | salivary duct carcinoma, Brenner tumour, apocrine carcinoma of the breast, prostate carcinoma (most cases) |
Androgen receptor, abbreviated AR, is receptor activated by androgens (testosterone, dihydrotestosterone).
Tumours with AR
- Salivary duct carcinoma +ve ~90% of cases.[1]
- Ovarian Brenner tumour.[2]
- Apocrine carcinoma of the breast - usu. smaller tumours.[3]
- Prostate carcinoma with amphicrine features.[4]
Antibodies
Various clone exist and they target different regions/variants; an incomplete list includes:
- AR N-terminus.
- AR C-terminus.
- AR v7.
See also
References
- ↑ Fan, CY.; Wang, J.; Barnes, EL. (Apr 2000). "Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.". Am J Surg Pathol 24 (4): 579-86. PMID 10757407.
- ↑ Kuhn, E.; Ayhan, A.; Shih, IeM.; Seidman, JD.; Kurman, RJ. (Dec 2013). "Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium.". Eur J Cancer 49 (18): 3839-49. doi:10.1016/j.ejca.2013.08.011. PMID 24012099.
- ↑ Honma, N.; Takubo, K.; Akiyama, F.; Sawabe, M.; Arai, T.; Younes, M.; Kasumi, F.; Sakamoto, G. (Aug 2005). "Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.". Histopathology 47 (2): 195-201. doi:10.1111/j.1365-2559.2005.02181.x. PMID 16045781.
- ↑ Prendeville, S.; Al-Bozom, I.; Compérat, E.; Sweet, J.; Evans, AJ.; Ben-Gashir, M.; Mete, O.; van der Kwast, TH. et al. (Dec 2017). "Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?". Histopathology 71 (6): 926-933. doi:10.1111/his.13330. PMID 28756619.